Matthew Dennis

Invesco Advisers, Inc. is a SEC-registered investment advisor headquartered in Atlanta, Georgia. They are a subsidiary of Invesco Group Services, Inc., ultimately held by Invesco Ltd. (NYSE: IVZ). The firm was founded in 1986 and previously known as Invesco Institutional NA, Inc. until April 2010 when Invesco Ltd. consolidated the businesses of their US investment advisors (Invesco AIM Advisors, Inc., Invesco AIM Capital Management, Inc., Invesco AIM Private Asset Management, Inc. and Invesco Global Asset Management NA, Inc.) under the name Invesco Advisers, Inc. They provide discretionary and non-discretionary investment advisory services to individuals, institutional and high net-worth clients through separate accounts, wrap fee programs and US registered investment companies and other Commingled Funds.

Fortis Investment Management (UK) Ltd. (FIM-UK) became Fischer Francis Trees & Watts (UK) Ltd. in October 2010, and refocused on fixed income investments. In the course of the integration of Fortis into BNP Paribas, the equity investments previously managed by FIM-UK were taken over by BNP Paribas Investment Partners (UK) Ltd., the dedicated asset management business of BNP Paribas SA (XP: BNP) in France. Established in 2003, FIM-UK is located in London. Their clients include institutions, high-net worth individuals and retail investors. In 2008 the firm absorbed ABN AMRO Asset Management Ltd., following the merger of the asset management activities of Fortis and ABN AMRO worldwide. In 2010 Fortis Investments merged with the existing BNP Paribas Investment Partners Group creating a global investment solutions provider which combines the best that large companies have to offer with the reactivity, specialization and entrepreneurial spirit of investment boutiques.

Aravas, Inc. develops innovative drugs for the treatment of serious and life-threatening conditions. It develops dry powder formulations for various therapeutic molecules, including antibiotics, corticosteroids, nucleic acids, and insoluble and soluble molecules. The firm’s products include AeroVanc, an inhaled dry powder form of vancomycin in a capsule-based inhaler to treat methicillin-resistant staphylococcus aureus infections in patients with cystic fibrosis or other lung-compromising conditions; and AeroCort, a high performance inhaled corticosteroid product for the treatment of asthma in children. The company was founded by Cory Berkland, Chris Marich, Robert N. Neville, Taneli Jouhikainen, Chal Lenge and George Laurence in March 2007 and is headquartered in Austin, TX.